InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,501.00
(
0.25%
)
US TECH 100
19,445.20
(
0.19%
)
Dow Jones
38,937.19
(
0.26%
)
Brent Oil
85.13
(
0.51%
)
Bitcoin
65,176.91
(
0.34%
)
Post# of 252257
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

NP1986

Send PM Follow Ignore
Followers 6
Posts 541
Boards Moderated 0
Alias Born 06/07/2011

NP1986

Re: pcrutch post# 125688

Friday, 08/26/2011 11:15:32 AM

Friday, August 26, 2011 11:15:32 AM

Post# of 252257

Why are they comparing it against DTIC/TMZ when TMZ isn't even approved for this indication?



Until recently, there weren't many approved treatment options for melanoma. Pfizer's phase III tremelimumab trial used the investigator's choice of DTIC or TMZ as the comparator. I don't see much wrong with using TMZ as a comparator.

Nevertheless, I can't really comment on Allovectin-7 itself.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up